ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Subcutaneous TRT injections reduce the number of men with high hematocrit
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 223322" data-attributes="member: 13851"><p><strong>Erythrocytosis in Subcutaneous Testosterone Replacement Therapy</strong></p><p><strong>Author links open overlay panel (2022)</strong></p><p><em>TWilliamson, JTrussler, AMcCullough</em></p><p></p><p></p><p><strong>Introduction</strong></p><p></p><p><em>Intramuscular (IM) testosterone replacement therapy (TRT) is commonly administered to treat symptomatic male hypogonadism and can result in improved libido, muscle strength, and bone density. However, as many as 40-66% of men receiving IM testosterone replacement therapy may develop erythrocytosis (hematocrit ≥53%), which can result in an increased risk of vascular complications including venous thromboembolic disease. In transgender men, subcutaneous (SC) injections of testosterone have been used with improvement in patient satisfaction while maintaining a similar testosterone exposure to IM injections. Additionally, SC testosterone has been shown to be more tolerable, with less pain during injection and increased potential for self-administration.</em></p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em><strong>To evaluate the rate of erythrocytosis observed in cisgender male patients undergoing SC injection of testosterone cypionate in comparison to published rates in the literature with IM testosterone cypionate.</strong></em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em>A retrospective review of cisgender male patients receiving SC testosterone replacement therapy between January 2021 and June 2021 was conducted. <strong>Patient charts were reviewed for testosterone dose, baseline hematocrit, baseline testosterone level, sex hormone-binding globulin level prior to starting therapy, and the most recent hematocrit and testosterone levels. The rate of erythrocytosis was determined as well as the change in hematocrit from baseline.</strong></em></p><p></p><p></p><p><strong>Results</strong></p><p><strong></strong></p><p><strong>94 men were included in the cohort. 32% of men developed new-onset erythrocytosis while receiving SC testosterone cypionate. The average weekly dose of testosterone was similar between those receiving weekly and biweekly injections (100.76mg vs 111.2mg, p=0.27).</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><em>The SC administration of testosterone cypionate in men with symptomatic hypogonadism appears to result in a reduced rate of erythrocytosis compared with rates published in the literature for IM injection therapy. This may aid to decrease the risk of erythrocytosis and associated complications. Further study is warranted to confirm these findings in a prospective cohort.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 223322, member: 13851"] [B]Erythrocytosis in Subcutaneous Testosterone Replacement Therapy Author links open overlay panel (2022)[/B] [I]TWilliamson, JTrussler, AMcCullough[/I] [B]Introduction[/B] [I]Intramuscular (IM) testosterone replacement therapy (TRT) is commonly administered to treat symptomatic male hypogonadism and can result in improved libido, muscle strength, and bone density. However, as many as 40-66% of men receiving IM testosterone replacement therapy may develop erythrocytosis (hematocrit ≥53%), which can result in an increased risk of vascular complications including venous thromboembolic disease. In transgender men, subcutaneous (SC) injections of testosterone have been used with improvement in patient satisfaction while maintaining a similar testosterone exposure to IM injections. Additionally, SC testosterone has been shown to be more tolerable, with less pain during injection and increased potential for self-administration.[/I] [B]Objective[/B] [I][B]To evaluate the rate of erythrocytosis observed in cisgender male patients undergoing SC injection of testosterone cypionate in comparison to published rates in the literature with IM testosterone cypionate.[/B][/I] [B]Methods[/B] [I]A retrospective review of cisgender male patients receiving SC testosterone replacement therapy between January 2021 and June 2021 was conducted. [B]Patient charts were reviewed for testosterone dose, baseline hematocrit, baseline testosterone level, sex hormone-binding globulin level prior to starting therapy, and the most recent hematocrit and testosterone levels. The rate of erythrocytosis was determined as well as the change in hematocrit from baseline.[/B][/I] [B]Results 94 men were included in the cohort. 32% of men developed new-onset erythrocytosis while receiving SC testosterone cypionate. The average weekly dose of testosterone was similar between those receiving weekly and biweekly injections (100.76mg vs 111.2mg, p=0.27). Conclusions [I]The SC administration of testosterone cypionate in men with symptomatic hypogonadism appears to result in a reduced rate of erythrocytosis compared with rates published in the literature for IM injection therapy. This may aid to decrease the risk of erythrocytosis and associated complications. Further study is warranted to confirm these findings in a prospective cohort.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Subcutaneous TRT injections reduce the number of men with high hematocrit
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top